Pancreatic Cancer Research

ResearcherThe University of OsakaNo recent work listed

Tadashi Watabe

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-8658-2395; OpenAlex author ID A5021151911. Sources: OpenAlex.

Their work

Papers
4 (first author 2, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
11
Papers, trials and grants by year

2020: 1 paper · 2021: 1 paper · 2022: 1 paper · 2023: 1 paper

Papers 4

  1. Immuno-PET and Targeted α-Therapy Using Anti-Glypican-1 Antibody Labeled with 89Zr or 211At: A Theranostic Approach for Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.2967/jnumed.123.266313↗
  2. Fibroblast activation protein targeted therapy using [177Lu]FAPI-46 compared with [225Ac]FAPI-46 in a pancreatic cancer model. First author DOI 10.1007/s00259-021-05554-2↗
  3. Evaluation of 64Cu-Labeled New Anti-EGFR Antibody NCAB001 with Intraperitoneal Injection for Early PET Diagnosis of Pancreatic Cancer in Orthotopic Tumor-Xenog… First author DOI 10.3390/ph14100950↗
  4. Theranostics Targeting Fibroblast Activation Protein in the Tumor Stroma: 64Cu- and 225Ac-Labeled FAPI-04 in Pancreatic Cancer Xenograft Mouse Models. Co-author DOI 10.2967/jnumed.119.233122↗

Closest collaborators

The 11 strongest of 11 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jun Hatazawa · 3 shared papers, 2020–2022 · strength 0.34
  2. Frederik Lars Giesel · 2 shared papers, 2020–2022 · strength 0.23
  3. Yuwei Liu · 2 shared papers, 2020–2022 · strength 0.23
  4. Noriyuki Tomiyama · 1 shared paper, 2023 · strength 0.15
  5. Tetsuji Naka · 1 shared paper, 2023 · strength 0.15
  6. Fukiko Hihara · 1 shared paper, 2021 · strength 0.10
  7. Chika Igarashi · 1 shared paper, 2021 · strength 0.10
  8. Yukie Yoshii · 1 shared paper, 2021 · strength 0.10
  9. Hiroki Matsumoto · 1 shared paper, 2021 · strength 0.10
  10. Makoto Ueno · 1 shared paper, 2021 · strength 0.10
  11. Tatsuya Higashi · 1 shared paper, 2021 · strength 0.10

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.